<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1729-519X</journal-id>
<journal-title><![CDATA[Revista Habanera de Ciencias Médicas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev haban cienc méd]]></abbrev-journal-title>
<issn>1729-519X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de la Habana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1729-519X2019000400607</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Sobrevida en pacientes con Esclerosis Lateral Amiotrófica]]></article-title>
<article-title xml:lang="en"><![CDATA[Survival in patients with Amyotrophic Lateral Sclerosis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Serra Ruiz]]></surname>
<given-names><![CDATA[Melissa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Serra Valdés]]></surname>
<given-names><![CDATA[Miguel Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de la Habana Instituto Nacional de Neurología y Neurocirugía ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de la Habana Hospital General Docente &#8220;Enrique Cabrera&#8221; ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>18</volume>
<numero>4</numero>
<fpage>607</fpage>
<lpage>623</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1729-519X2019000400607&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1729-519X2019000400607&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1729-519X2019000400607&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La esclerosis lateral amiotrófica (ELA) es la más frecuente del grupo heterogéneo de las enfermedades de la motoneurona.  Objetivo:  Caracterizar la sobrevida de los pacientes con diagnóstico de esclerosis lateral amiotrófica partiendo de factores relacionados con su comportamiento clínico en el Instituto Nacional de Neurología y Neurocirugía &#8220;Dr. José Rafael Estrada González&#8221; de a Habana, Cuba.  Material y Métodos: Se realizó una investigación descriptiva y retrospectiva de una serie de 147 casos de pacientes diagnosticados con ELA, por la confirmación clínica, neurofisiológica e imágenes, atendidos en la consulta multidisciplinaria en el periodo de octubre de 2005 a octubre de 2015, de los cuales ya han fallecido 110.  Resultados:  La mayor frecuencia de la enfermedad por grupos de edades estuvo entre 51 y 60 años. En los primeros 40 meses murió la mayor parte de los pacientes (80). La forma clínica espinal predominó en varones quienes, además, tuvieron mayor sobrevida, la bulbar prevaleció en mujeres. El mayor número de pacientes no tenía factores de riesgo. Entre las comorbilidades destacan la diabetes, hipertensión arterial, enfermedad cerebrovascular isquémica, neoplasias, hepatitis C, traumatismo craneal, asma bronquial y la cardiopatía isquémica, y hubo casos de la enfermedad en una misma familia.  Conclusiones:  La mayor sobrevida desde el diagnóstico de la enfermedad estuvo en el grupo de 51 a 60 años alcanzando algunos hasta 10 años. El promedio general de sobrevida estuvo entre 2 y 5 años. En los pacientes con comorbilidades, antecedentes familiares y forma bulbar, la sobrevida fue menor. La supervivencia al evaluar la efectividad del tratamiento con Riluzol no fue significativa.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Amyotrophic lateral sclerosis (ALS) is the most frequent disease in the heterogeneous group of disorders with motor neuron diseases.  Objective:  To characterize the survival of patients diagnosed with amyotrophic lateral sclerosis considering factors related to their clinical behavior at "Dr. Jose Rafael Estrada Gonzalez&#8221; National Institute of Neurology and Neurosurgery, Havana, Cuba.  Material and Methods:  A descriptive and retrospective research was conducted. The study included a case series of 147 patients diagnosed with ALS by clinical and neurophysiological confirmation and images. The patients were treated in the multidisciplinary consultation in the period from October 2005 to October 2015. A total of 110 of them already died.  Results:  The disease most often occurs between the ages of 51 and 60. In the first 40 months, most of the patients in the series died, for a total of 80 people. The spinal clinical form predominated in males who had higher survival; the bulbar form prevailed in women. Most of the patients had no risk factors. Diabetes, arterial hypertension, ischemic cerebrovascular disease, neoplasms, hepatitis C, head trauma, bronchial asthma and ischemic heart disease stand out as comorbidities. There were cases of the disease within a single family.  Conclusions:  The greatest survival from the diagnosis of the disease was observed in the group between 51 and 60 years of diagnosis of the disease, some of them reaching up to 10 years. The general average of survival was between 2 and 5 years. It was lower in patients with comorbidities, family history and bulbar form. After evaluating the effectiveness of the treatment with Riluzole, the survival was not significant.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[esclerosis lateral amiotrófica]]></kwd>
<kwd lng="es"><![CDATA[enfermedad de la motoneurona]]></kwd>
<kwd lng="es"><![CDATA[sobrevida]]></kwd>
<kwd lng="es"><![CDATA[factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[formas clínicas]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="es"><![CDATA[riluzol]]></kwd>
<kwd lng="en"><![CDATA[amyotrophic lateral sclerosis]]></kwd>
<kwd lng="en"><![CDATA[motor neuron disease]]></kwd>
<kwd lng="en"><![CDATA[survival]]></kwd>
<kwd lng="en"><![CDATA[risk factors]]></kwd>
<kwd lng="en"><![CDATA[clinical forms]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="en"><![CDATA[Riluzole]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown Robert Jr]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis lateral amiotrófica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<source><![CDATA[Principios de Medicina Interna]]></source>
<year>2016</year>
<edition>19a</edition>
<page-range>2631-6</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill Interamericana Editores, S.A]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedades de la motoneurona. Esclerosis Lateral Amiotrófica]]></article-title>
<source><![CDATA[Medicina Interna]]></source>
<year>2016</year>
<edition>18a</edition>
<page-range>1379-82</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaw Pamela]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis Lateral Amiotrófica]]></article-title>
<source><![CDATA[Tratado deMedicina Interna]]></source>
<year>2016</year>
<edition>25a</edition>
<page-range>2347-52</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pritzker D.N]]></surname>
<given-names><![CDATA[Abbas]]></given-names>
</name>
<name>
<surname><![CDATA[A.K]]></surname>
<given-names><![CDATA[Aster J.C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis lateral amiotrófica]]></article-title>
<source><![CDATA[Patología Humana]]></source>
<year>2017</year>
<edition>10ma</edition>
<page-range>841-8</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Neurological disease. Davidson's Principles and Practice of Medicine]]></source>
<year>2014</year>
<edition>22 Ed</edition>
<page-range>2230-80</page-range><publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raina]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis Lateral amiotrófica]]></article-title>
<source><![CDATA[Enfermedades de la neurona motora]]></source>
<year>2010</year>
<page-range>291-9</page-range><publisher-loc><![CDATA[Buenos Aires ]]></publisher-loc>
<publisher-name><![CDATA[Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Grunho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enteral feeding through endoscopic gastrostomy in amyotrophic lateral sclerosis patients]]></article-title>
<source><![CDATA[Nutr. Hosp]]></source>
<year>2016</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1015-21</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rianchoa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalob]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Sotob]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bercianoa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Por qué degeneran las motoneuronas? Actualización en la patogenia de la esclerosis lateral amiotrófica]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zapata-Zapata]]></surname>
<given-names><![CDATA[C. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Franco-Dáger]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Solano-Atehortúa]]></surname>
<given-names><![CDATA[J. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ahunca-Velásquez]]></surname>
<given-names><![CDATA[L. F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis lateral amiotrófica: actualización]]></article-title>
<source><![CDATA[Iatreia]]></source>
<year>2016</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>194-205</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camacho]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Esteban]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Paradas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Report by the Spanish Foundation for the Brain on the social impact of amyotrophic lateral sclerosis and other neuromuscular disorders]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2018</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-46</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ysasi]]></surname>
<given-names><![CDATA[G. C. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Prado]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Herrero]]></surname>
<given-names><![CDATA[M. V.]]></given-names>
</name>
<name>
<surname><![CDATA[Bach]]></surname>
<given-names><![CDATA[J. R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alternativas de tratamiento en pacientes con patologías neuromusculares y afecciones respiratorias]]></article-title>
<source><![CDATA[In Anales de la Facultad de Ciencias Médicas]]></source>
<year>2017</year>
<volume>50</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>79-88</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catalina]]></surname>
<given-names><![CDATA[Pinchak]]></given-names>
</name>
<name>
<surname><![CDATA[Pamela]]></surname>
<given-names><![CDATA[Salinas]]></given-names>
</name>
<name>
<surname><![CDATA[Francisco]]></surname>
<given-names><![CDATA[Prado]]></given-names>
</name>
<name>
<surname><![CDATA[María]]></surname>
<given-names><![CDATA[Herrero]]></given-names>
</name>
<name>
<surname><![CDATA[Gloria]]></surname>
<given-names><![CDATA[Giménez]]></given-names>
</name>
<name>
<surname><![CDATA[Carolina]]></surname>
<given-names><![CDATA[García]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización en el manejo respiratorio de pacientes con enfermedades neuromusculares]]></article-title>
<source><![CDATA[Arch. Pediatr. Urug]]></source>
<year>2018</year>
<volume>89</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-51</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akly]]></surname>
<given-names><![CDATA[M. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Schiava]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Melcom]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Gargiulo]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Bettini]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[de Ambrosi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio epidemiológico multicéntrico sobre esclerosis lateral amiotrófica en la Ciudad de Buenos Aires]]></article-title>
<source><![CDATA[Neurología Argentina]]></source>
<year>2017</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>225-30</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz-Gómez]]></surname>
<given-names><![CDATA[M. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz-Corredor]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diseño y validación de un sistema de clasificación para evaluar el grado de discapacidad de los pacientes con esclerosis lateral amiotrófica]]></article-title>
<source><![CDATA[Rev Neurol]]></source>
<year>2017</year>
<volume>64</volume>
<page-range>112-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riancho]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalo]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Soto]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Berciano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Por qué degeneran las motoneuronas? Actualización en la patogenia de la esclerosis lateral amiotrófica]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2019</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-37</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hardiman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Amyotrophic Lateral Sclerosis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Hardiman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Doherty]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurodegenerative Disorders]]></source>
<year>2011</year>
<page-range>143-66</page-range><publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Springer-Verlag]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enriquez-Marulanda]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe-Becerra]]></surname>
<given-names><![CDATA[J. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Granados]]></surname>
<given-names><![CDATA[A. M.]]></given-names>
</name>
<name>
<surname><![CDATA[Shinchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-intensity signal in the corticospinal tract in MRI as a sign of upper motor neuron lesion in amyotrophic lateral sclerosis: Case report and literature review]]></article-title>
<source><![CDATA[Acta Neurológica Colombiana]]></source>
<year>2017</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>99-103</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Swash]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[For the world federation of neurology research group on motor neuron diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[Amyotrophic lateral Sclerosis]]></source>
<year>2000</year>
<volume>1</volume>
<page-range>293-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mandrioli]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of ALS in Emilia Romagna Region. A population based Study]]></article-title>
<source><![CDATA[Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration]]></source>
<year>2014</year>
<volume>15</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>262-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pereira Silva]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aguiar Gusmão]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha Pithon]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Peixoto Gomes]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira Pinto]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerose lateral amiotrófica: descrição de aspectos clínicos e funcionais de uma série de casos numa região de saúde do nordeste do Brasil]]></article-title>
<source><![CDATA[Journal of Health &amp; Biological Sciences]]></source>
<year>2018</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>293-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Labra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Menon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Byth]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vucic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rate disease progression: a prognostic biomarker of ALS]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2016</year>
<volume>87</volume>
<page-range>628-32</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camacho Assef]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho Escalante]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez Mantilla]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho Assef]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[López Borroto]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[García Garriga]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of regenerative medicine in Cuba]]></article-title>
<source><![CDATA[Mediciego]]></source>
<year>2017</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>55-60</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carmona Espinazo]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Perteguer Huertas]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón Manoja]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[García Polo]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Moya Molina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atención clínica, toma de decisiones y soporte nutricional en pacientes con esclerosis lateral amiotrófica]]></article-title>
<source><![CDATA[Nutr. clin. diet. hosp]]></source>
<year>2016</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>200-5</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallardo]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Arantzamendi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Carvajal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión narrativa sobre la calidad de vida relacionada con la salud en personas con esclerosis lateral amiotrófica]]></article-title>
<source><![CDATA[Medicina Paliativa]]></source>
<year>2018</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>105-13</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caroline]]></surname>
<given-names><![CDATA[Ingre]]></given-names>
</name>
<name>
<surname><![CDATA[Roos Per]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fredrik]]></surname>
<given-names><![CDATA[Piehl]]></given-names>
</name>
<name>
<surname><![CDATA[Freya]]></surname>
<given-names><![CDATA[Kamel]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[Fang]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo para esclerosis lateral amiotrófica]]></article-title>
<source><![CDATA[Clinical Epidemiology]]></source>
<year>2015</year>
<volume>7</volume>
<page-range>181-93</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schuster]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hardiman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Bede]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics]]></article-title>
<source><![CDATA[BMC Neurology]]></source>
<year>2017</year>
<volume>17</volume>
<page-range>73-83</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grigorakos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lazarescu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Myrinathefs]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Antonopoulos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Agathonikou]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sotiriou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients with amyotrophic lateral sclerosis in the intensive care unit]]></article-title>
<source><![CDATA[Curr Opin Neurol Sci]]></source>
<year>2016</year>
<volume>1</volume>
<page-range>12-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cordesse]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sidorok]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Schimmel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Holstein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meininger]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coordinated care affects hospitalization and prognosis in amyotrophic lateral sclerosis: a cohort study]]></article-title>
<source><![CDATA[BMC Health Serv Res]]></source>
<year>2015</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scull Torres]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cuidados paliativos en esclerosis lateral amiotrófica]]></article-title>
<source><![CDATA[Medimay]]></source>
<year>2018</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-76</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pisa]]></surname>
<given-names><![CDATA[F.E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospitalizations due to respiratory failure in patients with Amyotrophic Lateral Sclerosis and their impact on survival: a population based cohort Study]]></article-title>
<source><![CDATA[BMC Pulmonary Medicine]]></source>
<year>2016</year>
<volume>16</volume>
<page-range>136-45</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez-Bermejo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Morélot-Panzini]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Tanguy]]></surname>
<given-names><![CDATA[M. L.]]></given-names>
</name>
<name>
<surname><![CDATA[Meininger]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Pradat]]></surname>
<given-names><![CDATA[P. F.]]></given-names>
</name>
<name>
<surname><![CDATA[Lenglet]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[.Desnuelle]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial]]></article-title>
<source><![CDATA[The Lancet Neurology]]></source>
<year>2016</year>
<volume>15</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1217-27</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Talman]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Duong]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Vucic]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Venkatesh]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Henderson]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Macdonnell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort]]></article-title>
<source><![CDATA[BMJ open]]></source>
<year>2016</year>
<volume>6</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Knibb]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Una herramienta clínica para predecir supervivencia en la ELA]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2016</year>
<volume>87</volume>
<page-range>1361-7</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[M-L]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Holbrook]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicting functional decline and survival in amyotrophic lateral sclerosis]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2017</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farrero]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Antón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Egea]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Almaraz]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Masa]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Utrabo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Normativa sobre el manejo de las complicaciones respiratorias de los pacientes con enfermedad neuromuscular. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)]]></article-title>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2013</year>
<volume>49</volume>
<page-range>306-13</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schuster]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hardiman]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Bede]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics]]></article-title>
<source><![CDATA[BMC Neurology]]></source>
<year>2017</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-83</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[LO]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Toledo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Montes de Oca]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Esclerosis lateral amiotrófica: un reto actual para las neurociencias]]></article-title>
<source><![CDATA[16 de Abril]]></source>
<year>2018</year>
<volume>57</volume>
<numero>267</numero>
<issue>267</issue>
<page-range>55-63</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
